期刊
BIOMOLECULES
卷 11, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/biom11081095
关键词
myofibroblast; fibrosis; wound healing; anti-scarring therapy; transforming growth factor-beta 1
资金
- National Natural Science Foundation of China (NSFC) [82050410449, 81921004, 8130060]
- QBiotics Group (Australia)
- Dunhill Medical Trust (UK) [RPGF2006\248]
Myofibroblasts play diverse roles in pathophysiological processes, with potential as therapeutic targets. Despite challenges in specifically targeting them, research is progressing towards understanding their formation, function, regulation, and developing interventions to prevent fibrosis and promote wound healing.
Myofibroblasts are contractile, alpha-smooth muscle actin-positive cells with multiple roles in pathophysiological processes. Myofibroblasts mediate wound contractions, but their persistent presence in tissues is central to driving fibrosis, making them attractive cell targets for the development of therapeutic treatments. However, due to shared cellular markers with several other phenotypes, the specific targeting of myofibroblasts has long presented a scientific and clinical challenge. In recent years, myofibroblasts have drawn much attention among scientific research communities from multiple disciplines and specialisations. As further research uncovers the characterisations of myofibroblast formation, function, and regulation, the realisation of novel interventional routes for myofibroblasts within pathologies has emerged. The research community is approaching the means to finally target these cells, to prevent fibrosis, accelerate scarless wound healing, and attenuate associated disease-processes in clinical settings. This comprehensive review article describes the myofibroblast cell phenotype, their origins, and their diverse physiological and pathological functionality. Special attention has been given to mechanisms and molecular pathways governing myofibroblast differentiation, and updates in molecular interventions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据